Increase/Decrease in Cash: The total change in cash for the company over the given period.
TG Therapeutics, Inc. (TGTX) had Increase/Decrease in Cash of $350.26M for the most recently reported fiscal quarter, ending 2026-09-30.
| Income Statement Financials | |
$259.94M |
|
$55.46M |
|
$42.08M |
|
$217.86M |
|
$174.04M |
|
$85.90M |
|
$-12.04M |
|
$73.86M |
|
$73.86M |
|
$55.46M |
|
$55.46M |
|
$55.46M |
|
$55.46M |
|
$85.90M |
|
$86.05M |
|
140.79M |
|
155.93M |
|
$0.39 |
|
$0.35 |
|
| Balance Sheet Financials | |
$1.17B |
|
-- |
|
$420.81M |
|
$1.59B |
|
$260.53M |
|
$745.63M |
|
$759.60M |
|
$1.02B |
|
$572.13M |
|
$572.13M |
|
$572.13M |
|
151.16M |
|
| Cash Flow Statement Financials | |
$66.60M |
|
$-7.50M |
|
$291.17M |
|
$80.49M |
|
$430.75M |
|
|
Increase/Decrease in Cash |
$350.26M |
$72.53M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.50 |
|
-- |
|
-- |
|
0.57 |
|
1.30 |
|
83.81% |
|
33.05% |
|
33.05% |
|
-- |
|
28.42% |
|
21.34% |
|
$65.97M |
|
-- |
|
-- |
|
-- |
|
0.16 |
|
0.22 |
|
0.62 |
|
144.32 |
|
9.69% |
|
9.69% |
|
3.48% |
|
4.21% |
|
$3.78 |
|
$0.42 |
|
$0.43 |
|